Rheumatology And Clinical Immunology

Recent developments in basic science and clinical rheumatology make it appropriate at this time to create a volume devoted to the immunology of rheumatic diseases. The impact of molecular biology, gene cloning, and new technologies for establishing hybridomas and T-cell lines in the laboratory is now beginning to be felt in clinical medicine. There is a general air of excitement and a feeling that we stand on the threshold of a new era in molecular medicine and clinical science. It is this excitement that we have tried to capture in this book. This volume is divided into five sections entitled Basic Mechanisms, Autoimmunity, Classical Concepts of Rheumatic Diseases, Pathogenetic Mechanisms, and Therapy. This is not an arbitrary arrangement but represents our belief that from an understanding of basic mechanisms of disease pathogenesis will come new and more successful forms of treatment for the sufferers of rheumatic disorders. We have tried in the selection of authors to choose internationally recognized experts who have both a scientific and a clinical orientation to their subjects. We believe the marriage of clinical and basic disciplines represents the best hope for rapid knowledge transfer from the laboratory to the clinic, where such knowledge can be used to improve patient health.

A wide-ranging account of the immunological mechanisms that underlie many rheumatic diseases, such as rheumatoid arthritis, ankylosing spondylitis and SLE, and the development of effective and rational new therapies.

Thoroughly revised and updated, the 7th Edition of Rheumatology remains a leading text in this fast-changing field, keeping you abreast of recent advances in medications, therapies, clinical trials, and much more. Dr. Mark Hochberg and his team of expert authors and editors cover everything you need to know -- from basic scientific principles to practical clinical management strategies, all in a user-friendly, accessible manner.

A huge number of therapeutic studies has been published in rheumatology and clinical immunology. This number grows substantially by the year. As such, it becomes increasingly difficult to keep track of this multitude of studies and the ensuing therapeutic trends. Further to this, a particular study can be referred to in a variety of ways, either as a shortened version of the title or an acronym, adding to the confusion. The book Clinical Trials in Rheumatology, Second Edition, provides an updated summary of the important studies in the field for easy reference. Every study is shown with name, acronym (if in existence), authors, complete citation, study design, and a short overview of the trial's data and main conclusions. An acronym finder is supplied at the beginning of the book. This book is a valuable reference tool for rheumatologists and other clinical specialties, as well as for research scientists interested in immunomodulatory and selected other drug therapies in rheumatologic diseases.

With the increasing use of immune checkpoint inhibitors (ICI) across various cancers, the trends for indication at earlier stages, and the use of combination immunotherapy, the frequency of ICI-induced immune-related adverse events (irAE) is expected to grow substantially. Management of these irAE is challenging as it requires not only consideration of the toxicity but also risk-benefit ratios with respect to the primary cancer. Several rheumatic irAE have been reported with ICI therapy including arthritis, myositis, polymyalgia-like syndromes, sicca/Sjogren-like manifestations, and several other less common systemic autoimmune features commonly associated with connective tissue disease. This handbook provides clinicians with a comprehensive overview of the management of rheumatic irAE that develop from cancer immunotherapy. It focuses on the irAE seen with ICI, the most frequently used agents in treating cancer. It provides an overview of cancer immunology, immunotoxicity, and immunotherapies such as ICI, cytokine-based therapy, and CART. It examines the epidemiology, clinical manifestations, diagnosis, differential diagnosis, and treatment of a variety of rheumatic immune-related adverse events arising from these therapies. Chapters also cover cancer immunotherapy in patients with preexisting rheumatic diseases such as inflammatory arthritis and other connective tissue disorders. The book helps clinicians to distinguish the current types of cancer immunotherapy and general toxicity patterns, recognize and diagnose rheumatic clinical syndromes, understand the pathogenesis of irAE, and consider risk–benefit ratios when managing patients with rheumatic irAE. Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy is an essential resource for physicians and related professionals, residents, fellows, graduate students and nurses alike in rheumatology, clinical immunology, oncology, and internal medicine.